Interestingly, circulating levels of AHR ligands are decreased in individuals with MS (Rothhammer et al., 2016), raising the possibility that reduced ligand availability underpins defective AHR signaling in autoimmune diseases. The gene discussed is AHR; the disease is myeloid sarcoma.